Zoetis, a manufacturer of animal health products, recorded net profit of US$601 million in the first quarter of 2026, with an increase of 6% in earnings per share compared to the same period in 2025.
For the quarter it was US$646 million, or US$1.53 per diluted share, representing an increase of 2% and 9%, respectively.
Revenue totaled US$2.3 billion in the first quarter, an increase of 3% compared to the same period last year.
“The companies demonstrated greater price sensitivity, resulting in a drop in veterinary visits and weaker demand for innovative products,” Zoetis CEO Kristin Peck said in a statement.
Cattle performance was favored by the expanded use of parasiticides in response to the New World screwworm outbreak. Revenue in the International segment totaled US$1.1 billion.
Companion animal sales grew 15%, led by the parasiticides portfolio (including Simparica Trio) and diagnostics.
International revenue was positively influenced by operational changes linked to the fiscal year alignment, which contributed around US$100 million to the quarter’s revenue due to the end of the one-month delay in publishing the results of foreign subsidiaries.
Forecast
For the year to 2026, Zoetis revised its projections downwards, with revenue between US$9.68 billion and US$9.96 billion. The estimate for adjusted diluted earnings per share was set between $6.85 and $7, while reported net income is expected to be between $2.68 billion and $2.76 billion.
